Chinese Investigators Identify Novel NSCLC & Small Molecule Drugs by Integrated Microarray Analysis

May 14, 2019 | Biomarker, Chinese Research, Molecular Research, Non-Small Cell Lung Cancer, NSCLC, Prognosis

Chinese Research

A group of major Chinese academic medical centers collaborated on basic research to identify non-small-cell lung cancer (NSCLC) biomarkers and small molecule drug candidates. The team understands that NSCLC remains a leading cause of cancer death. In the study they identified novel biomarkers associated with the pathogenesis of NSCLC hoping to provide new diagnostic and therapeutic approaches to NSCLC.

The team downloaded microarray datasets of GSE18842, GSE30219, GSE31210, GSE32863 and GSE40791 from the Gene Expression Omnibus database. This is an international public repository that archives and freely distributes high-throughput gene expression and other functional genomics data sets. Created in 2000, it has evolved with rapidly changing technologies and now accepts high-throughput data for many other applications.

The group identified differential expressed genes (DEGs) between MSCLC and normal samples via the limma package. The team performed a development of protein-protein interaction (PPI) network, module analysis and enrichment analysis leveraging bioinformatics tools. Thereafter, they were able to validate the expression and prognostic value of hub genes. Validation was made possible by GEPIA database and real-time quantitative PCR. Based on the differential expressed genes, they utilized the CMap database and identified candidate small molecules for NSCLC.

The team found a total of 408 overlapping DEGs including 109 up-regulated and 296 down-regulated genes. 300 nodes and 1283 interactions were obtained from the PPI network. The most significant biological process and pathway enrichment of DEGs were responses to wounding and cell adhesion molecules respectively.

The Chinese team concluded that based on the gene expression profiles of 696 NSCLC samples and 237 normal samples, they first disclosed that PTTG1, TYMS, ECT2, COL1A1, SPP1 and CDCA5 could act as the promising novel diagnostic and therapeutic targets for NSCLC. They will continue to pursue research to clarify the molecular mechanisms of NSCLC initiation and progression.

The Team

Medical School of Nantong University, Nantong 226001, People’s Republic of China

The Hand Surgery Research Center, Department of Hand Surgery, Affiliated Hospital of Nantong University, Nantong 226001, People’s Republic of China

Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, People’s Republic of China

Department of Biochemistry & Molecular Biology, Nantong University, Nantong, Jiangsu 226001, People’s Republic of China


Pin It on Pinterest